PMID- 11698925
OWN - NLM
STAT- MEDLINE
DCOM- 20020104
LR  - 20181130
IS  - 1521-2076 (Electronic)
IS  - 1521-2076 (Linking)
VI  - 6
IP  - 5
DP  - 2001 Oct
TI  - Bone loss in premenopausal women on long-term suppressive therapy with thyroid 
      hormone.
PG  - 3
AB  - BACKGROUND: The effects on bone metabolism of long-term treatment with thyroid 
      hormone given at suppressive doses have been debated. OBJECTIVE: To determine 
      whether long-term thyroxine therapy in the premenopausal period is a risk factor 
      for the development of secondary osteoporosis and whether women receiving this 
      therapy have increased bone loss during the premenopausal period. PATIENTS AND 
      METHODS: The study enrolled a select group of 19 premenopausal women of mean ages 
      39 +/- 8 years suffering from differentiated thyroid gland carcinoma. All 
      subjects had undergone total thyroidectomy and subsequently initiated thyroxine 
      suppressive therapy. At the beginning of our study, the women had been on 
      suppressive therapy for 9.4 +/- 6.4 years. Laboratory results were performed to 
      exclud other possible factors for secondary osteoporosis. This prospective study 
      of bone mineral density (BMD) was conducted over a 4-year period on all subjects 
      using the method of dual photon x-ray absorptiometry (DXA) of the spine and the 
      femoral neck and also by the method of single-photon absorptiometry (SPA) of the 
      distal radius. RESULTS: At the beginning of this study, 2 subjects had osteopenia 
      in the spine and 2 had osteopenia in the femoral neck; they had been on 
      suppressive thyroxine therapy for 10 years. Osteopenia in the distal radius was 
      found in 4 subjects. Overall, 8 of the 19 women had osteopenia at the beginning 
      of the study. One year later, after the second BMD measurement, no statistically 
      significant loss of bone mass occurred in any region of the skeleton in any of 
      the patients. However, a review of the individual scores revealed osteopenia in 6 
      patients at the distal radius; bone loss also occurred at the spine and the 
      femoral neck in several women, but not to the extent that would establish 
      osteopenia. After the 4 years, BMD measurements indicated significant bone loss. 
      CONCLUSION: Our results suggest that women who begin long-term ( ~ 10 years) 
      thyroxine therapy in the premenopausal period can develop osteopenia by the 
      beginning of menopause.
FAU - Sijanovic, S
AU  - Sijanovic S
AD  - Department of Gynecology and Obstetrics, University Hospital Osijek, Osijek, 
      Croatia. sinisa.sijanovic@os.hinet.hr
FAU - Karner, I
AU  - Karner I
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medscape Womens Health
JT  - Medscape women's health
JID - 100844142
RN  - 0 (Biomarkers)
RN  - 0 (Thyroid Hormones)
RN  - 9002-71-5 (Thyrotropin)
RN  - Q51BO43MG4 (Thyroxine)
RN  - SY7Q814VUP (Calcium)
MH  - Adult
MH  - Biomarkers
MH  - Bone Density/drug effects
MH  - Calcium/blood
MH  - Combined Modality Therapy
MH  - Croatia/epidemiology
MH  - Female
MH  - Humans
MH  - Long-Term Care
MH  - Middle Aged
MH  - Osteoporosis/*chemically induced/epidemiology
MH  - Osteoporosis, Postmenopausal/chemically induced/epidemiology
MH  - Premenopause/*drug effects
MH  - Prospective Studies
MH  - Risk Factors
MH  - Thyroid Hormones/blood
MH  - Thyroid Neoplasms/surgery/*therapy
MH  - *Thyroidectomy
MH  - Thyrotropin/antagonists & inhibitors/metabolism
MH  - Thyroxine/*administration & dosage/*adverse effects/blood
EDAT- 2001/11/08 10:00
MHDA- 2002/01/10 10:01
CRDT- 2001/11/08 10:00
PHST- 2001/11/08 10:00 [pubmed]
PHST- 2002/01/10 10:01 [medline]
PHST- 2001/11/08 10:00 [entrez]
AID - 408957 [pii]
PST - ppublish
SO  - Medscape Womens Health. 2001 Oct;6(5):3.